Deal could give Lilly full diabetes deck
Eli Lilly and Co.’s diabetes partnership with Boehringer Ingelheim GmbH represents a new kind of disease-focused strategy that some consultants think is key to pharma companies’ futures.
Health Care & Insurance
Articles
Q&A: Derek Bang
Derek Bang, practice leader of health care advisory services at the Crowe Horwath accounting firm in Indianapolis, spent a week in March studying health care in the United Kingdom, especially its universal health care program. He was surprised by the “daily barrage of criticism” he heard about the National Health Service, but also found that the United Kingdom and United States face very similar issues when it comes to constraining growth in health care costs.
UPDATE: Analysts praise Lilly diabetes deal with Boehringer
The deal Eli Lilly and Co. announced Tuesday morning with Boehringer Ingelheim GmbH sounded a lot like a baseball trade—with five drugs and payments to be named later—but analysts and investors generally liked what they heard.
Lilly agrees to pay up to $1.2B for diabetes drugs
A complex deal with Boehringer Ingelheim also gives the German company rights to two experimental Lilly insulins.
Lilly partner moves up timetable for diabetes drug
Amylin Pharmaceuticals Inc., rebuffed twice in its bid for U.S. approval of a weekly diabetes drug, will meet its timetable and submit a heart-safety study to regulators by the end of 2011, its CEO said.
Bill would let Indiana pharmacies collect old meds
A bill authored by Republican Rep. Kevin Mahan of Hartford City would revise state law so that pharmacies could accept unused prescription drugs from customers and dispose of them securely and safely.
Closed dental company working to transfer patients
Citing cash-flow problems, Allcare Dental and Dentures shut down operations in 14 states, including Indiana, last week.
Lilly’s Solpura may lack data to prove effectiveness
Outside advisers to the FDA will meet Jan. 12 to review whether the drug should be approved for people with pancreas insufficiency caused by cystic fibrosis, chronic pancreatitis or other conditions.
IndyCar deal creates series-branded insurance plan
Open-wheel race series signs three-year sponsorship pact with Dallas-based Global Corporate Alliance.
Lilly bumped up federal lobbying in third quarter
The Indianapolis-based drugmaker spent $2.1 million in the three months that ended Sept. 30, a 5-percent increase from the same quarter last year and a jump of more than 30 percent from the $1.6 million it spent in this year's second quarter.
New doc lifts Community breast biz
Community Health Network wooed Dr. Robert J. Goulet Jr. to join its breast-surgery team from the Indiana University Simon Cancer Center. The move fits nicely with Community’s focus on breast-care services and the economics of health care.
Latest iPhone app: Baby EKG
Mobile medicine has arrived. Decatur County Memorial Hospital in Greensburg became the first hospital in Indiana to start using AirStrip OB, a patient-monitoring system that sends things like the heartbeat waves of patients directly to physicians’ iPhones, BlackBerrys or other mobile devices.
Lilly, other big drugmakers shut out by FDA in 2010
Regulators cleared 21 medicines, the fewest since 2007, for sale last year. It was the first time in a decade that Pfizer Inc., the world’s largest drugmaker, as well as Lilly, Merck & Co. and Bristol-Myers Squibb Co. were shut out at the same time, according to agency records.
Indiana Medicaid cuts likely to be followed by more
The Office of Medicaid Policy and Planning has approved a series of emergency rules that it expects to save a total of $4.1 million over the next six months, but that will make up for only a small portion of the $31.4 million shortfall the agency anticipates for the fiscal year.
Roche acquires Marcadia Biotech
Marcadia Biotech Inc., a Carmel-based biopharmaceutical company founded by prominent scientists from Eli Lilly and Co. in 2006, has been acquired by Swiss life sciences giant Roche.
Conseco brass agree to settle 8-year-old suit for $41.5M
The suit accused CEO Gary Wendt, President Bill Shea, Chief Financial Officer Charles Chokel and Chief Accounting Officer Jim Adams of engaging in a “massive and systematic coverup of … actual debts and losses through complex accounting, misleading disclosures, and irregular accounting practices.”
New company taking over troubled Standard Life
State Insurance Commissioner Stephen Robertson said agreements have been reached for the $1.7 billion in policies and financial obligations of Carmel-based Standard Life Insurance Co. to be assumed by Guggenheim Life and Annuity Co.
Group questions growth of pharmacy schools
Two weeks before Manchester College announced a $35 million gift to help open a pharmacy school, a national trade group suggested there are too many pharmacy schools already.
Amylin and Lilly seek expanded Byetta approval
Eli Lilly and Co. and Amylin Pharmaceuticals Inc. said Wednesday they are asking the Food and Drug Administration to expand approval for their type 2 diabetes drug Byetta, which could bolster sales as the companies try to get approval for a new, longer-lasting version of the drug.